Misplaced Pages

Obexelimab is an experimental drug developed to treat IgG4-related disease and lupus. It works as a "bifunctional, non-cytolytic, humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells."

References

1. Perugino, Cory A; Wallace, Zachary S; Zack, Debra J; Quinn, Shauna M; Poma, Allen; Fernandes, Ana D; Foster, Paul; DeMattos, Steve; Burington, Bart; Liu, Hang; Allard-Chamard, Hugues; Smith, Nathan; Kai, Xin; Xing, Kelly; Pillai, Shiv; Stone, John H (August 2023). "Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial". The Lancet Rheumatology. 5 (8): e442–e450. doi:10.1016/S2665-9913(23)00157-1. PMID 38251576. S2CID 260176880.
2. Merrill, Joan T.; Guthridge, Joel; Smith, Miles; June, Joshua; Koumpouras, Fotios; Machua, Wambui; Askanase, Anca; Khosroshahi, Arezou; Sheikh, Saira Z.; Rathi, Gaurav; Burington, Bart; Foster, Paul; Matijevic, Mark; Arora, Sujata; Wang, Xiaodong; Gao, Minggeng; Wax, Stephen; James, Judith A.; Zack, Debra J. (December 2023). "Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind , Randomized, Placebo-Controlled , Phase 2 Trial". Arthritis & Rheumatology. 75 (12): 2185–2194. doi:10.1002/art.42652. S2CID 265521796.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs developed by Bristol Myers Squibb
• Monoclonal antibodies
• Pharmacology stubs